Roben G. Gieling

Newcastle Upon Tyne, ENG NE18ST, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Butylated Neuropeptide Antagonist Targeting Hypoxia-Induced GRPR Overexpression in Small Cell Lung Cancer.

Butylated Neuropeptide Antagonist Targeting Hypoxia-Induced GRPR Overexpression in Small Cell Lung Cancer.

Journal: International journal of molecular sciences

Published: September 23, 2025

Next generation organoid engineering to replace animals in cancer drug testing.

Next generation organoid engineering to replace animals in cancer drug testing.

Journal: Biochemical pharmacology

Published: January 31, 2023

A Novel Mechanism of Ataxia Telangiectasia Mutated Mediated Regulation of Chromatin Remodeling in Hypoxic Conditions.

A Novel Mechanism of Ataxia Telangiectasia Mutated Mediated Regulation of Chromatin Remodeling in Hypoxic Conditions.

Journal: Frontiers in cell and developmental biology

Published: June 03, 2021

Preclinical Evaluation of Ureidosulfamate Carbonic Anhydrase IX/XII Inhibitors in the Treatment of Cancers.

Preclinical Evaluation of Ureidosulfamate Carbonic Anhydrase IX/XII Inhibitors in the Treatment of Cancers.

Journal: International journal of molecular sciences

Published: November 05, 2019

A new method for the high-precision assessment of tumor changes in response to treatment.

A new method for the high-precision assessment of tumor changes in response to treatment.

Journal: Bioinformatics (Oxford, England)

Published: July 27, 2017

Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer.

Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer.

Journal: International journal of cancer

Published: July 16, 2017

The Sulfamate Small Molecule CAIX Inhibitor S4 Modulates Doxorubicin Efficacy.

The Sulfamate Small Molecule CAIX Inhibitor S4 Modulates Doxorubicin Efficacy.

Journal: PloS one

Published: May 19, 2016

Corrigendum: NFκB1 is a suppressor of neutrophil-driven hepatocellular carcinoma.

Corrigendum: NFκB1 is a suppressor of neutrophil-driven hepatocellular carcinoma.

Journal: Nature communications

Published: September 22, 2015

Dissemination via the lymphatic or angiogenic route impacts the pathology, microenvironment and hypoxia-related drug response of lung metastases.

Dissemination via the lymphatic or angiogenic route impacts the pathology, microenvironment and hypoxia-related drug response of lung metastases.

Journal: Clinical & experimental metastasis

Published: January 13, 2015

Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.

Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.

Journal: Journal of enzyme inhibition and medicinal chemistry

Published: October 28, 2014

NFκB1 is a suppressor of neutrophil-driven hepatocellular carcinoma.

NFκB1 is a suppressor of neutrophil-driven hepatocellular carcinoma.

Journal: Nature communications

Published: October 24, 2014

[18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941.

[18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941.

Journal: Molecular cancer therapeutics

Published: February 22, 2013

Showing 1-12 of 15

Last Updated: 09/26/2026